Lecanemab and donanemab (Kisunla), another anti-amyloid treatment, won approval based on evidence that they slowed cognitive ...

The Food and Drug Administration's approval in 2023 of lecanemab—a novel Alzheimer's therapy shown in clinical trials to ...

Only around 74% of the city's kindergarteners have an MMR vaccine, far below the state average and herd immunity for the ...

Teens who are engaged increase their academic skills, engage other teens and contribute positively to the community. That is ...

No TV before bed. It is poor sleep hygiene to look at screens to scroll or watch a show before bedtime, but what if you ...

In a recent study, researchers found adverse events were rare and manageable among clinic patients with very mild or mild Alzheimer's disease who received lecanemab infusions.

The study has been published ahead of print in the prestigious journal ‘Diabetes’, published by the American Diabetes ...

ALTON - Siteman Cancer Center, Alton Memorial Hospital and Senior Services Plus (SSP) are once again hosting a Bingo Lunch ...

Breakthrough discovery of new MODY subtype challenges assumptions, highlights need for genetic testing in diabetes care.

Which Missouri high school athlete had the best week? Each week, SBLive scours the state for the top spring sports performers ...

The Food and Drug Administration's approval in 2023 of lecanemab - a novel Alzheimer's therapy shown in clinical trials to modestly slow disease progression - was met with enthusiasm by many in the ...

Cancer treatment with a cell-based immunotherapy causes mild cognitive impairment, a Stanford Medicine team found. They also identified compounds that could treat it.